Scientists track Long-Term safety of experimental AMD therapy

NCT ID NCT07660640

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Perceive Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows people with advanced dry age-related macular degeneration who previously received a one-time injection of the experimental treatment VOY-101. Researchers are monitoring participants over the long term to check for any side effects related to the treatment. The goal is to understand the safety profile of VOY-101 beyond the initial study period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VOY-101
What this could lead to: If successful, this long-term safety data could support further development of VOY-101 as a potential treatment for advanced dry age-related macular degeneration.
What could go wrong: This is an observational follow-up study, not a new treatment trial. It cannot prove whether VOY-101 works; it only tracks safety over time. The number of participants is small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (AMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Ophthalmic Consultants of Boston

Boston, Massachusetts, 02114, United States
Retina Consultants of Texas

Bellaire, Texas, 77401, United States
Sourasky Medical Center - Ichilov

Tel Aviv, 6423906, Israel
University of Utah

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.